Somewhat Negative Press Coverage Somewhat Unlikely to Affect Mustang Bio (MBIO) Stock Price

News headlines about Mustang Bio (NASDAQ:MBIO) have been trending somewhat negative on Sunday, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mustang Bio earned a coverage optimism score of -0.02 on Accern’s scale. Accern also gave headlines about the company an impact score of 48.0331370398627 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

MBIO has been the subject of several recent analyst reports. Zacks Investment Research cut Mustang Bio from a “buy” rating to a “hold” rating in a research note on Tuesday, May 22nd. ValuEngine upgraded Mustang Bio from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

MBIO stock traded down $0.15 during trading on Friday, hitting $6.41. 44,800 shares of the company’s stock were exchanged, compared to its average volume of 55,984. The stock has a market cap of $177.85 million and a price-to-earnings ratio of -8.55. Mustang Bio has a 52-week low of $5.87 and a 52-week high of $13.35.

Mustang Bio (NASDAQ:MBIO) last posted its earnings results on Monday, May 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). The company had revenue of $0.05 million during the quarter. research analysts predict that Mustang Bio will post -1.01 EPS for the current fiscal year.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma.

Recommended Story: NASDAQ Stock Market Explained

Insider Buying and Selling by Quarter for Mustang Bio (NASDAQ:MBIO)

Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with's FREE daily email newsletter.

Leave a Reply